A new glutamate release inhibitor with demonstrated potential to improve the Quality of Life for Parkinson’s disease patients.
CVXL-0107 is a first in-class glutamate release inhibitor for the treatment of adult patients with Parkinson’s disease experiencing postural disturbances and/or dyskinesia. CVXL-0107 is currently in Phase IIa involving 30 patients. The product had previously demonstrated clinical efficacy for parkinsonian motor symptoms and dyskinesia treatment.
Glutamate is the major excitatory neurotransmitter in the basal ganglia, the brain structure involved in movement control. Through three distinct action sites, inhibition of glutamate release is expected to improve the life of Parkinson’s patients by:
– Reducing cortical input into the striatum, widely thought to be a cause of dyskinesia¹
– Improving motor symptoms, by decreasing globus pallidus-mediated movement inhibition²
– Slowing down neurodegeneration inhibiting glutamate-mediated excitotoxicity on the substantia nigra³
CVXL-0107 is expected to demonstrate clinical efficacy ongoing Phase IIa study.
1. Huot, P., Johnston, T. H., Koprich, J. B., Fox, S. H. & Brotchie, J. M. The pharmacology of L-DOPA-induced dyskinesia in Parkinson’s disease. Pharmacol. Rev. 65, 171–222 (2013).
2. Wichmann, T. & DeLong, M. R. Functional and pathophysiological models of the basal ganglia. Curr. Opin. Neurobiol. 6, 751–8 (1996).
3. AlDakheel, A., Kalia, L. V & Lang, A. E. Pathogenesis-targeted, disease-modifying therapies in Parkinson disease. Neurotherapeutics 11, 6–23 (2014).
4. Jankovic, J. & Poewe, W. Therapies in Parkinson’s disease. Curr. Opin. Neurol. 25, 433–47 (2012).